We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"CPRX set to report Q2 earnings on Aug. 6, with EPS estimate at $0.58 and revenues at $139.19 million.\",\"1\":\"Firdapse sales likely rose on strong demand, while Fycompa may have dipped due to a patent expiration.\",\"2\":\"Agamree sales are expected to grow amid increasing prescriber engagement and expanded commercial push.\"}
Catalyst Pharmaceuticals (CPRX - Free Report) is scheduled to report its second-quarter 2025 earnings results on Aug. 6, after market close.
The Zacks Consensus Estimate for CPRX’s earnings per share in the to-be-reported quarter is currently pegged at 58 cents, while the same for its total revenues is pinned at $139.19 million.
Let's take a look at how things are shaping up for the upcoming quarterly release.
Factors to Consider Regarding CPRX’s Q2 Earnings
Catalyst Pharmaceuticals recognizes revenues under two segments — Product revenue and License and other revenue.
Under Product revenue, Catalyst Pharmaceuticals recognizes revenues from the sale of its three marketed products — Firdapse, Fycompa and Agamree. Firdapse is CPRX’s FDA-approved drug in the United States for treating Lambert-Eaton myasthenic syndrome (LEMS). The drug is also approved for treating LEMS in several other geographies.
Firdapse sales are likely to have rosen in the second quarter of 2025 compared to the same period last year, driven by organic sales growth due to strong demand, higher prescription rates among LEMS patients and continued diagnosis of new cases. The Zacks Consensus Estimate for Firdapse sales in the to-be-reported quarter is currently pegged at $88 million, while our model estimate for the same is pinned at $87 million.
Year to date, shares of CPRX have gained 4.1% compared with the industry’s 4.4% growth.
Image Source: Zacks Investment Research
In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for epilepsy drug Fycompa CIII from Eisai Co., Ltd. This acquisition diversified the company’s portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023.
However, Fycompa sales are likely to have declined in the second quarter of 2025 due to the expiration of one of its patents in May 2025. The Zacks Consensus Estimate for the drug’s sales in the to-be-reported quarter is currently pegged at $25.9 million, while our model estimate for the same is pinned at $26.7 million.
Catalyst Pharmaceuticals also markets Agamree, which is FDA-approved for treating Duchenne Muscular Dystrophy in patients aged two years and older. CPRX acquired exclusive rights to Agamree from Santhera Pharmaceuticals through a licensing agreement in 2023.
Agamree sales are likely to have increased in the upcoming quarterly results, driven by continued growth and increasing prescriber engagement. The Zacks Consensus Estimate for the drug’s sales in the to-be-reported quarter is currently pegged at $25.1 million, while our model estimate for the same is pinned at $25.2 million.
Catalyst Pharmaceuticals' research and development expenses are expected to have increased in the second quarter, reflecting investments in label-expansion efforts for Agamree. Selling, general, and administrative costs are likely to have risen, driven by continued spending on commercial activities for both Firdapse and Agamree.
CPRX’s Earnings Surprise History
Catalyst Pharmaceuticals has an impeccable earnings surprise history so far. The company beat estimates on each of the trailing four reported quarters, delivering an average earnings surprise of 28.15%. In the last reported quarter, CPRX reported an earnings surprise of 28.3%.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Catalyst Pharmaceuticals this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you can see below.
Earnings ESP: Catalyst Pharmaceuticals has an Earnings ESP of -4.35%, as the Zacks Consensus Estimate, which is pegged at earnings of 58 cents per share, is greater than the most accurate estimate of earnings of 55 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Catalyst Pharmaceuticals has a Zacks Rank #2 at present.
Catalyst Pharmaceuticals, Inc. Price and Consensus
DNLI stock has plunged 29.1% year to date. It beat on earnings in two of the last four quarters and missed on the other two occasions, delivering an average surprise of 4.42%. Denali Therapeutics is expected to report second-quarter earnings soon.
Acadia Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +17.43% and a Zacks Rank #3 at present.
Shares of ACAD have soared 31% year to date. It beat on earnings in three of the trailing four quarters and missed once, delivering an average surprise of 19.58%. Acadia Pharmaceuticals is slated to report second-quarter results on Aug. 6, after market close.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
Key Takeaways
Catalyst Pharmaceuticals (CPRX - Free Report) is scheduled to report its second-quarter 2025 earnings results on Aug. 6, after market close.
The Zacks Consensus Estimate for CPRX’s earnings per share in the to-be-reported quarter is currently pegged at 58 cents, while the same for its total revenues is pinned at $139.19 million.
Let's take a look at how things are shaping up for the upcoming quarterly release.
Factors to Consider Regarding CPRX’s Q2 Earnings
Catalyst Pharmaceuticals recognizes revenues under two segments — Product revenue and License and other revenue.
Under Product revenue, Catalyst Pharmaceuticals recognizes revenues from the sale of its three marketed products — Firdapse, Fycompa and Agamree. Firdapse is CPRX’s FDA-approved drug in the United States for treating Lambert-Eaton myasthenic syndrome (LEMS). The drug is also approved for treating LEMS in several other geographies.
Firdapse sales are likely to have rosen in the second quarter of 2025 compared to the same period last year, driven by organic sales growth due to strong demand, higher prescription rates among LEMS patients and continued diagnosis of new cases. The Zacks Consensus Estimate for Firdapse sales in the to-be-reported quarter is currently pegged at $88 million, while our model estimate for the same is pinned at $87 million.
Year to date, shares of CPRX have gained 4.1% compared with the industry’s 4.4% growth.
Image Source: Zacks Investment Research
In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for epilepsy drug Fycompa CIII from Eisai Co., Ltd. This acquisition diversified the company’s portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023.
However, Fycompa sales are likely to have declined in the second quarter of 2025 due to the expiration of one of its patents in May 2025. The Zacks Consensus Estimate for the drug’s sales in the to-be-reported quarter is currently pegged at $25.9 million, while our model estimate for the same is pinned at $26.7 million.
Catalyst Pharmaceuticals also markets Agamree, which is FDA-approved for treating Duchenne Muscular Dystrophy in patients aged two years and older. CPRX acquired exclusive rights to Agamree from Santhera Pharmaceuticals through a licensing agreement in 2023.
Agamree sales are likely to have increased in the upcoming quarterly results, driven by continued growth and increasing prescriber engagement. The Zacks Consensus Estimate for the drug’s sales in the to-be-reported quarter is currently pegged at $25.1 million, while our model estimate for the same is pinned at $25.2 million.
Catalyst Pharmaceuticals' research and development expenses are expected to have increased in the second quarter, reflecting investments in label-expansion efforts for Agamree. Selling, general, and administrative costs are likely to have risen, driven by continued spending on commercial activities for both Firdapse and Agamree.
CPRX’s Earnings Surprise History
Catalyst Pharmaceuticals has an impeccable earnings surprise history so far. The company beat estimates on each of the trailing four reported quarters, delivering an average earnings surprise of 28.15%. In the last reported quarter, CPRX reported an earnings surprise of 28.3%.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Catalyst Pharmaceuticals this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you can see below.
Earnings ESP: Catalyst Pharmaceuticals has an Earnings ESP of -4.35%, as the Zacks Consensus Estimate, which is pegged at earnings of 58 cents per share, is greater than the most accurate estimate of earnings of 55 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Catalyst Pharmaceuticals has a Zacks Rank #2 at present.
Catalyst Pharmaceuticals, Inc. Price and Consensus
Catalyst Pharmaceuticals, Inc. price-consensus-chart | Catalyst Pharmaceuticals, Inc. Quote
Stocks to Consider
Here are some stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Denali Therapeutics (DNLI - Free Report) currently has an Earnings ESP of +3.54% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
DNLI stock has plunged 29.1% year to date. It beat on earnings in two of the last four quarters and missed on the other two occasions, delivering an average surprise of 4.42%. Denali Therapeutics is expected to report second-quarter earnings soon.
Acadia Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +17.43% and a Zacks Rank #3 at present.
Shares of ACAD have soared 31% year to date. It beat on earnings in three of the trailing four quarters and missed once, delivering an average surprise of 19.58%. Acadia Pharmaceuticals is slated to report second-quarter results on Aug. 6, after market close.